Abstract 5661
Background
Chemotherapy (CT) plays a vital role as conversion treatment for initially unresectable or borderline resectable colorectal cancer (CRC). Targeted therapies are recommended with CT for conversion therapy; however, their role in conversion of initially unresectable tumours has not been elucidated. This meta-analysis evaluated the role of targeted therapies for conversion aimed at R0 resection in KRAS WT mCRC.
Methods
We conducted a literature search for randomized controlled trials (RCTs) in PubMed, Embase and Cochrane library evaluating the role of anti EGFR and anti VEGF as conversion therapies. A comparison was performed for anti-EGFR + CT vs. anti-VEGF + CT (Gp. A) and anti-EGFR + CT vs. CT (Gp. B). R0 resection rate and objective response rate (ORR) were the primary outcomes; with overall survival (OS), progression free survival (PFS) and safety evaluated as the secondary outcomes. Primary outcomes and safety were presented as relative risk (RR) and 95% confidence interval (CI), whereas survival was presented as hazard ratio (HR) and 95%CI.
Results
We identified 8 RCTs from the potential 81 studies. In Gp. A, a fixed effects model was used for analysis; and showed that although non-significant, anti EGFR + CT had better R0 resection rate (RR 1.44, 95% CI 0.91,2.27; p = 0.1156; I2 = 0%) and ORR (RR 1.05, 95% CI 0.88, 1.24; p = 0.6039; I2 = 0%) compared with anti VEGF + CT. OS with anti EGFR + CT was significantly longer than anti VEGF + CT (HR: 0.64; CI 0.47, 0.86; p = 0.0036; I2 = 0%); however, PFS was numerically better in anti EGFR + CT. Compared with CT alone, anti EGFR + CT resulted in significantly higher R0 resection rate (RR 1.85, 95% CI 1.15,2.98; p = 0.0107; I2 = 57.16%) and ORR (RR 1.19, 95% CI 1.11, 1.28; p < 0.0001; I2 = 0%). In Gp. B, only PFS was significantly longer with anti EGFR + CT vs. CT (HR: 0.85; 95% CI 0.74, 0.98; p = 0.0015; I2 = 45.60%), and not OS. Safety evaluation showed anti EGFR + CT with significantly greater adverse events than CT alone (RR: 1.26; 95% CI: 1.18, 1.35; p < 0.0001).
Conclusions
In conclusion, anti EGFR + CT was an effective conversion therapy compared with anti VEGF + CT and CT in patients with initially unresectable mCRC; however, frequency of AEs was more with targeted therapy.
Clinical trial identification
Legal entity responsible for the study
Merck Serono Co. Ltd.
Funding
Merck Serono Co. Ltd.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract